Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of CancerĢƵ 38th Annual Meeting (SITC 2023)
SAN DIEGO--(BUSINESS WIRE)--Nov 3, 2023--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of new preclinical data from the companyĢƵ CLD-201 ...

